Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A in Idiopathic Overactive Bladder
NCT00910520Phase 3Completed
- Sponsor
- Allergan
- Start
- Sep 2009
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing onabotulinumtoxinA with Placebo (2 arms). Primary endpoint: Change From Baseline in Number of Daily Episodes of Urinary Incontinence at 12 weeks. Started Sep 2009; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00910520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00910520.